St George's Hospital selects MDI's PCR-based assay for MRSA
21 Oct 2010
Molecular Detection Inc. has announced that its Detect-Ready
MRSA assay has received its first independent validation in a study
conducted at St George's Healthcare NHS Trust, London, one of the UK's
leading teaching hospitals .
In a comparative study of the Detect-Ready assay and two other
widely used PCR-based MRSA screening tests, the St George's
researchers confirmed that the performance of the Detect-Ready MRSA
assay was better than or equivalent to
Becton Dickinson's GeneOhm MRSA ACP Assay and Roche's
LightCycler MRSA Advanced Test.
Based on the results of this study, MDI's Detect-Ready is now
used as the molecular assay of choice in the MRSA screening programs
at St George's.
"Following this comparative study, St George's has adopted the
Detect-Ready MRSA kit for routine MRSA screening in our intensive
care unit (ICU), as a result of the high sensitivity and specificity
we observed and the kits' ease-of-use and cost-effectiveness," said
Dr. Cassie Pope, Clinical Scientist of St George's.
"The Detect-Ready MRSA kit provides a number of advantages,
including software that provides non-subjective interpretation and
straight-forward reporting. The inclusion of multiple gene targets
in the Detect-Ready MRSA test appears to minimize false positive
results, reducing both unnecessary resource deployment and the
inconvenience to patients wrongly labeled as MRSA positive," said
Kay Capaldi, Chief Biomedical Scientist of St George's.
"St. George's is one of the most respected research hospitals in
the UK, so we are especially pleased to receive their independent
validation confirming the excellent sensitivity and specificity of
our Detect-Ready MRSA assay," said Todd Wallach, CEO of MDI. "We
believe our Detect-Ready MRSA assay offers healthcare providers a
high-performance MRSA screening test with an unmatched combination
of accuracy, speed, flexibility and cost-effectiveness, and we look
forward to the results of additional comparative studies currently
Drug-resistant MRSA (methicillin-resistant Staphylococcus
aureus) infections are a growing problem in healthcare
facilities around the world. In the UK all in-patients are screened
and hospitals have to keep within strict MRSA infection targets. All
incidents have to be reported to the hospital monitoring bodies.
The Detect-Ready MRSA kit is a qualitative real-time PCR in
vitro diagnostic test for the direct detection of MRSA nasal
colonization to aid in the prevention and control of MRSA infections
in hospitals and other healthcare settings.
The proprietary technology in the Detect-Ready kits
provides a unique differential diagnosis engine that produces highly
accurate results, minimizing the false positives and false negatives
experienced with other MRSA screening kits. Samples for testing are
simple to obtain using nasal swabs and the assay's ready-to-use
pre-mixed reagents require only the addition of patient sample to
run the test, which provides results in less than three hours.
Unlike other testing products that require special handling,
Detect-Ready kits are off-the-shelf room temperature-stabilized and
require no refrigeration. Detect-Ready kits are compatible with
multiple rt-PCR platforms currently found in clinical laboratories,
including the Roche LightCycler, Qiagen Rotor-Gene and Cepheid
SmartCycler. The flexibility to leverage existing infrastructure and
equipment to run Detect-Ready assays eliminates the need for
additional hospital capital investment.
The Detect-Ready MRSA assay kit has received the CE mark
certification for sales in the European Union. It is distributed in
the UK and Ireland by Launch Diagnostics. The assay is also
currently available in Germany, Switzerland, Spain, Austria and
1. Pope CF, Capaldi K. Comparison of the analytical sensitivity
of three commercial real time PCR assays for the detection of MRSA.
Poster session presented at: Seventh International Conference of the
Hospital Infection Society; 2010 Oct 10-13; Liverpool, UK.